Please check your internet connection and try again.
# Lorazepam (representative benzodiazepine)
## Overview
Lorazepam is a benzodiazepine medication primarily used for its anxiolytic, sedative, hypnotic, and anticonvulsant properties.
## Primary Indications
* **Anxiety Disorders:** Short-term management of anxiety symptoms.
* **Insomnia:** Short-term treatment of insomnia characterized by difficulty falling asleep or staying asleep.
* **Seizure Disorders:** Management of status epilepticus and other acute seizure activity.
* **Preanesthetic Medication:** To reduce anxiety and provide sedation before surgical procedures.
## Adult Dosing
* **Anxiety:** 0.5 mg to 2 mg orally every 6 to 8 hours as needed.
* **Insomnia:** 1 mg to 2 mg orally at bedtime. Not recommended for long-term use.
* **Status Epilepticus:** 4 mg intravenously (IV) or intramuscularly (IM). May repeat dose in 5 to 10 minutes if seizures persist, not to exceed 8 mg in a 12-hour period. Dosing for initial management may vary by protocol.
* **Preanesthetic:** 2 mg to 4 mg IM given 2 hours before surgery.
## Pediatric Dosing
Pediatric dosing is highly variable and should be guided by expert consultation and specific indication.
* **Seizures:** Limited data; typically 0.05 mg/kg IV/IM per dose, not to exceed 2 mg per dose, every 5-10 minutes as needed. Maximum total dose is not well established for pediatrics.
* **Anxiety/Sedation:** Dosing is not well established and should be individualized.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary.
* **Renal Impairment:** No specific dose adjustment is routinely recommended, but use with caution.
* **Elderly:** Start with lower doses (e.g., 0.5 mg to 1 mg orally once or twice daily) and titrate slowly due to increased sensitivity and risk of side effects.
## Contraindications
* Known hypersensitivity to lorazepam or other benzodiazepines.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
Common: Drowsiness, dizziness, weakness, unsteadiness, fatigue.
Less common: Confusion, depression, amnesia, ataxia, blurred vision.
Serious: Respiratory depression, paradoxical reactions (e.g., excitement, rage), dependence, withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other sedatives):** Additive CNS depression, increased risk of sedation, respiratory depression, coma, and death.
* **Theophylline/Aminophylline:** May decrease the sedative effects of lorazepam.
* **Valproic acid:** May decrease lorazepam clearance, potentially increasing lorazepam levels.
## Monitoring
* Respiratory rate, oxygen saturation, and level of consciousness, especially with IV administration or in combination with other CNS depressants.
* Signs of dependence and withdrawal, particularly with prolonged use.
* Effectiveness for the intended indication.
## Clinical Pearls
* Lorazepam has a relatively long half-life and is metabolized by glucuronidation, which may be a safer option in patients with hepatic impairment compared to some other benzodiazepines.
* Avoid abrupt discontinuation due to potential for withdrawal symptoms. Tapering is recommended.
* Intramuscular absorption can be slower and more variable than IV.
* Use for insomnia should be limited to short-term treatment due to risk of tolerance and dependence.
***
**Disclaimer:** This information is intended for clinical use and is not exhaustive. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions.
